Literature DB >> 18979162

The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women.

Jaak Jürimäe1, Toivo Jürimäe, Aire Leppik, Tatjana Kums.   

Abstract

The association of body fat mass (FM) with bone mineral mass (BMC) and bone mineral density (BMD) has been attributed to a mechanical load exerted on the skeleton by FM and by the effect of different hormones. The aim of the present study was to determine whether there is a relationship between ghrelin, adiponectin, and leptin with BMC and BMD in healthy postmenopausal women (n = 88; age, 68.9 +/- 6.8 years; body mass index, 27.4 +/- 3.6 kg/m(2)). Body composition, BMC, and BMD were derived by dual-energy X-ray absorptiometry. Waist-to-hip (WHR) and waist-to-thigh (WTR) ratios were also obtained. Ghrelin was associated with total BMC (beta = -0.945; P = 0.0001), total BMD (beta = -0.959; P = 0.0001), lumbar spine BMD (beta = -0.945; P = 0.0001), and femoral neck BMD (beta = -0.957; P = 0.0001), and remained associated (P < 0.041) in different analyses that controlled for measured body composition and hormonal and insulin resistance values. However, the associations between ghrelin and measured bone mineral values were no longer significant (P > 0.149) when adjusted for body fat distribution values (WHR, WTR). Adiponectin was significantly related to total BMC (beta = -0.931; P = 0.0001), total BMD (beta = -0.940; P = 0.0001), lumbar spine BMD (beta = -0.937; P = 0.0001), and femoral neck BMD (beta = -0.940; P = 0.0001) values, and these relationships remained significant (P < 0.019) after adjusting for measured body fat, hormonal, and insulin resistance values but not when adjusted for fat-free mass (FFM; P > 0.106). In addition, significant associations of leptin with total BMC (beta = 0.912; P = 0.0001), total BMD (beta = 0.907; P = 0.0001), lumbar spine BMD (beta = 0.899; P = 0.0001), and femoral neck BMD (beta = 0.906; P = 0.0001) were found. These associations remained significant (P < 0.010) in different analyses that controlled for hormonal and insulin resistance values, but the associations between leptin and bone mineral values were no longer significant (P > 0.145) when adjusted for specific body composition values (WHR, WTR, FM, and FFM). In conclusion, it appears that the influence of plasma ghrelin, adiponectin, and leptin levels on BMC and BMD values is mediated or confounded by the specific body composition parameters in healthy postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18979162     DOI: 10.1007/s00774-008-0861-5

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  45 in total

Review 1.  Relationships among body mass, its components, and bone.

Authors:  I R Reid
Journal:  Bone       Date:  2002-11       Impact factor: 4.398

2.  Ghrelin directly regulates bone formation.

Authors:  Nobuhiro Fukushima; Reiko Hanada; Hitoshi Teranishi; Yoshihiko Fukue; Toshiaki Tachibana; Hiroshi Ishikawa; Shu Takeda; Yasuhiro Takeuchi; Seiji Fukumoto; Kenji Kangawa; Kensei Nagata; Masayasu Kojima
Journal:  J Bone Miner Res       Date:  2004-12-27       Impact factor: 6.741

3.  Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways.

Authors:  Yusuke Shinoda; Masayuki Yamaguchi; Naoshi Ogata; Toru Akune; Naoto Kubota; Toshimasa Yamauchi; Yasuo Terauchi; Takashi Kadowaki; Yasuhiro Takeuchi; Seiji Fukumoto; Toshiyuki Ikeda; Kazuto Hoshi; Ung-il Chung; Kozo Nakamura; Hiroshi Kawaguchi
Journal:  J Cell Biochem       Date:  2006-09-01       Impact factor: 4.429

4.  Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast.

Authors:  Kazuya Oshima; Akihide Nampei; Morihiro Matsuda; Masanori Iwaki; Atsunori Fukuhara; Jun Hashimoto; Hideki Yoshikawa; Iichiro Shimomura
Journal:  Biochem Biophys Res Commun       Date:  2005-06-03       Impact factor: 3.575

5.  Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group.

Authors:  P Ravn; G Cizza; N H Bjarnason; D Thompson; M Daley; R D Wasnich; M McClung; D Hosking; A J Yates; C Christiansen
Journal:  J Bone Miner Res       Date:  1999-09       Impact factor: 6.741

6.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

7.  Adiponectin as a novel determinant of bone mineral density and visceral fat.

Authors:  L Lenchik; T C Register; F C Hsu; K Lohman; B J Nicklas; B I Freedman; C D Langefeld; J J Carr; D W Bowden
Journal:  Bone       Date:  2003-10       Impact factor: 4.398

8.  Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women.

Authors:  S Harris; G E Dallal; B Dawson-Hughes
Journal:  Calcif Tissue Int       Date:  1992-01       Impact factor: 4.333

9.  Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women.

Authors:  Miyao Matsubara; Shoji Maruoka; Shinji Katayose
Journal:  Eur J Endocrinol       Date:  2002-08       Impact factor: 6.664

Review 10.  Leptin and the skeleton.

Authors:  Tom Whipple; Neil Sharkey; Laurence Demers; Nancy Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

View more
  36 in total

Review 1.  Type 2 diabetes and bone fractures.

Authors:  Kendall F Moseley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

Review 2.  Marrow fat metabolism is linked to the systemic energy metabolism.

Authors:  Beata Lecka-Czernik
Journal:  Bone       Date:  2011-07-04       Impact factor: 4.398

3.  Influence of High-Fat Diet on Bone Tissue: An Experimental Study in Growing Rats.

Authors:  G Rezende Yanagihara; R Carminati Shimano; J Atsuko Tida; J Suzuki Yamanaka; S Yasuyo Fukada; J P Mardegan Issa; A C Shimano; J M Tavares
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

4.  Adiponectin is associated with bone strength and fracture history in paralyzed men with spinal cord injury.

Authors:  C O Tan; R A Battaglino; A L Doherty; R Gupta; A A Lazzari; E Garshick; R Zafonte; L R Morse
Journal:  Osteoporos Int       Date:  2014-07-01       Impact factor: 4.507

5.  Sex Differences in the Effects of Weight Loss Diets on Bone Mineral Density and Body Composition: POUNDS LOST Trial.

Authors:  Amir Tirosh; Russell J de Souza; Frank Sacks; George A Bray; Steven R Smith; Meryl S LeBoff
Journal:  J Clin Endocrinol Metab       Date:  2015-03-31       Impact factor: 5.958

6.  Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients.

Authors:  J Mohiti-Ardekani; H Soleymani-Salehabadi; M B Owlia; A Mohiti
Journal:  J Bone Miner Metab       Date:  2013-09-20       Impact factor: 2.626

Review 7.  Role of Marrow Adipocytes in Regulation of Energy Metabolism and Bone Homeostasis.

Authors:  Jillian Cornish; Tao Wang; Jian-Ming Lin
Journal:  Curr Osteoporos Rep       Date:  2018-04       Impact factor: 5.096

8.  The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women.

Authors:  D Lee Alekel; Marta D Van Loan; Kenneth J Koehler; Laura N Hanson; Jeanne W Stewart; Kathy B Hanson; Mindy S Kurzer; C Theodore Peterson
Journal:  Am J Clin Nutr       Date:  2009-11-11       Impact factor: 7.045

9.  Visceral fat is a negative predictor of bone density measures in obese adolescent girls.

Authors:  Melissa Russell; Nara Mendes; Karen K Miller; Clifford J Rosen; Hang Lee; Anne Klibanski; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

10.  Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density.

Authors:  Kemal Ağbaht; Alper Gürlek; Jale Karakaya; Miyase Bayraktar
Journal:  Endocrine       Date:  2009-03-14       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.